Missing IUS arms? We want to describe a couple of cases that serve to demonstrate that the hormone capsule of the Mirena® intrauterine system (IUS) can dislocate during removal thus changing its appearance. As a result, careful examination of the device is required to prevent further unnecessary investigations. A 58-year-old woman presented to her general practitioner for removal of a Mirena IUS as it was no longer required. It had been inserted at the practice 7 years previously to provide the progestogen component of her hormone replacement therapy. At the time of removal the cervix and the IUS threads were visualised. More traction than usual was required on the threads to remove the device. On inspection it appeared that the horizontal arms had become detached as they were not evident and the vertical main stem of the IUS had been removed with the hormone release capsule attached. The patient was asymptomatic and was allowed home. A transvaginal ultrasound scan was performed on an outpatient basis. The scan demonstrated echogenic specks at either end of the endometrium in longitudinal section, and in one case a few were noted within the lateral walls of the uterus. It was queried whether these represented the arms of the IUS. The patient was then referred to the gynaecology department, for consideration for operative hysteroscopy to remove the retained arms.

A 50-year-old woman presented to the colposcopy clinic with moderate dyskaryotic smears. She had undergone two previous long-acting release contraceptive IUSs. On this occasion colposcopy examination was limited because of unsatisfactory views of the squamo-columnar junction. It was decided the patient would have a further LLETZ treatment with removal and reinsertion of the Mirena IUS under general anaesthesia. At the time of the procedure it was noted that the IUS threads were visible and the internal cervix os was tightly closed. More traction than usual was required on the threads to remove the device. On inspection it was thought that the arms had become detached, the long stem of the device with the hormone release capsule present was attached to the threads. A saline hysteroscopy was therefore performed to locate the IUS arms. Good views of the entire cavity failed to demonstrate the presence of IUS arms or perforation. The LLETZ procedure was performed and a new IUS inserted. The patient underwent an uneventful post-operative recovery.

In both cases, when the removed IUS was re-examined, it became apparent that the entire device had been removed from the uterine cavity. The arms were still attached to the main stem of the IUS. The hormone release capsule, usually situated at the base of the vertical stem, had migrated up the shaft, trapping the arms and bringing them together in the midline, making it appear as if they had been detached (Figure 1). The majority of IUS are removed without difficulty. There are no published cases of IUS arms becoming detached. However, an intrauterine-retained hormone release capsule following IUS removal has been documented.1 The common theme in the two patients described above and Forrest et al.'s patient1 is difficult retrieval of the device requiring more traction on the threads than normal. This presumably led to the hormone capsule becoming dislodged, either migrating up the device and getting stuck covering the arms or becoming detached altogether. Clinicians should always check IUS devices after removal. They should also be aware that after a difficult removal the capsule can migrate and obscure the arms but the device remains complete. Knowledge of this possibility will prevent patients being subjected to unnecessary investigations and interventions to find ‘missing’ IUS arms and for appropriate consideration for operative hysteroscopy to remove the retained arms.

The whole of the IUS device is radio-opaque and can be located with either X-ray or ultrasound.2 Transvaginal ultrasound is the first-line investigation because it provides the best line investigation because it provides the best images to help determine whether or not the IUS is correctly sited within the uterus. The vertical stem of the IUS is visualised in the sagittal plane with multiple reflective parallel planes and in the axial plane as a single echogenic focus.3 However, in the cases reported here the vertical stem was seen in the uterus unless it is possible to obtain a coronal view.4 In view of this difficulty abdominal X-ray would confirm whether or not the horizontal arms of the IUS were within the pelvis. This would be useful, especially prior to embarking on hysteroscopic investigation.

References
2 Schering. Contra-indications, warnings, etc. Mirena Insertion Instructions, June 2007.

Reply We would like to take the opportunity to respond to Dr Torbe et al.'s letter,1 which describes an extremely rare, isolated case report of hormone cylinder dislocations in the Mirena® intrauterine system (IUS) similar to the ones described by the authors who have been received by the company’s Pharmacovigilance and Quality Assurance Unit. The company’s investigations have shown that these cases could not be attributed to a quality defect of the product. Difficult removal has been found as the underlying cause, and no further adverse effect in the Mirena user is mentioned in the majority of cases.

To make physicians aware of this extremely rare situation, and to avoid unnecessary interventions in search of ‘missing’ Mirena arms, the company has recently introduced the following statement into its patient Information for Mirena: “After removal of Mirena®, the system should be checked to be intact. During difficult removals, single cases have been reported of the hormone being sliding over the horizontal arms and hiding them together inside the cylinder. This situation does not require further intervention once completeness of the device has been ascertained. The knobs of the horizontal arms usually prevent complete detachment of the cylinder from the T-body.”

Implementation of this statement into the local product information is currently ongoing in all countries where Mirena is marketed, and it was submitted at the beginning of December 2008 to the Medicines and Healthcare products Regulatory Agency (MHRA) to be implemented in the UK.

Jussi Pirjola
Director, Quality Management Bayer Schering Pharma Oy, PO Box 415, 20101 Turku, Finland

Sarah Rybowski,
Medical Advisor, Women’s Healthcare,
Bayer Public Limited Company, Strawberry Hill, Newbury, UK.
E-mail: sarah.rybowski@bayerhealthcare.com

Serious morbidity with long-term IUD retention
We have recently encountered four patients with serious intraperitoneal sepsis over an 18-month interval (2007/2008). Each was associated with long-term retention of a copper intrauterine device (IUD), which was identified as the likely source of infection. The IUDs had been in situ for 8, 15, 18 and 20 years, respectively. Three women were several years into their menopause. All four women presented as systemically unwell with a complex pelvic mass. One had uterine obstruction at the site of the abscess, simulating gynaecological malignancy. In all cases laparotomy was technically difficult owing to the inflammatory pelvic mass adhering to bowel. Intermediate or prolonged hospitalisation resolved and, without invasive surgical care, two of the women would probably have died.

Pelvic actinomycosis was reported in the two patients’ histology. Cultures of frank pus grew Actinomyces israelii. Long-term inflammation-like organisms (ALOs) had been reported on histology smear of the fourth woman. In 2004 she had undergone appendectomy, which showed
Letters to the editor

severe subserosal inflammation without mucosal inflammation leading to the conclusion that the source was elsewhere within the abdomen or pelvis. It is speculative that this episode could usefully be increased among general practitioners.

This can lead to the device being free in

IntrauterineContraceptionNov07.pdf [Accessed 10 August 2008].


Reply

With regard to the four cases of serious pelvic infection described by Pillai et al., the Clinical Effectiveness Unit (CEU) acknowledges that long-term removal of an intrauterine device (IUD) is associated with infection and that the presence of actinomyces pelvic abscesses increases with duration of use. For this reason, Faculty of Sexual and Reproductive Healthcare (FSRH) Guidance recommends that an IUD is removed at the end of its licensed duration or when no longer required. In women having an IUD inserted between the age of 40 years and the menopause, FSRH Guidance recommends that, based on expert opinion, the risk of infection in the 20 days following replacement of an IUD outweighs the risk of extending use until the menopause. In this situation, if the IUD is not removed within 1 year after the last menstrual period (LMP), or 2 years after the menopause if the LMP occurs under the age of 50 years.

Intrauterine Contraception, 2002. London, UK: fpa, October 2007. Intrauterine contraception. E-mail: louise.melvin@ggc.scot.nhs.uk

References


Pillai et al. highlighted the potential for life-threatening infection and a lack of awareness of the need for IUD removal among some IUD users and health professionals. Current FSRH Guidance does not emphasise the need to advise patients about the importance of IUD removal when no longer required and about the potential risks of long-term IUD retention. We are grateful to Dr Pillai and colleagues for bringing this to our attention and we shall ensure that a recommendation to this effect is included in future updates of the Guidance on ‘Contraception for Women Aged Over 40 Years’ and ‘Intrauterine Contraception’.

Case reports are a useful source of evidence where no other evidence exists. We would encourage others to report complications that are particularly rare, serious or associated with prolonged contraceptive use.

Louise Melvin, MRCOG, MFSRH
Director, FSRH Clinical Effectiveness Unit (CEU) and Consultant in Sexual and Reproductive Health, Sandymount, Glasgow, UK.

Funding

Letters to the editor


IUS producing a TAC

I recently saw a very unusual patient in whom an intrauterine system (IUS) appeared to produce a trigeminal autonomic cephalalgia (TAC).

The patient, a 39-year-old woman, was fortunate never to have had a headache until the events reported here. In early 2007, the patient started to complain of severe menstruation. Her periods were heavy and lasted 14 days, and necessitated the use of 15–20 sanitary pads a day. Tranexamic acid 1000 mg qds was tried initially for 8 weeks but the heavy bleeding continued. Non-steroidal anti-inflammatory drugs were tried for many months resulting in a mild improvement. In desperation, the patient was referred to a gynaecologist who felt that the next step was to insert a levonorgestrel-releasing IUS. This was duly done. Within 6 hours of inserting the IUS the attacks started. All the patient’s attacks (averaging 5–7 attacks/day) were similar. All the attacks were left sided. She claimed that if the IUS was looked at with the side of the patient, she could not have her child. An attack started with pain to the side of the left eye that the patient described as unbearable, like the worst toothache ever. Associated with the pain was paresthesia from the left eye, although the pain was so bad the patient also cried with her right eye. Her palpebral fissure narrowed, her nose ran and her eye became pink. Her face felt strange and numb though painful. Touching her face, or brushing her hair or her teeth, did not trigger an attack. The attacks continued daily for 4 weeks until the patient came to our attention.

As she entered the room, an attack started. Following the attack I removed the patient’s IUS very easily and gave her a zolmitriptan nasal spray. In case she had further attacks I was happy to see her 7 days later, at which time she appeared to be a completely different person. She had suffered one further attack some 6 hours after the IUS was removed and a further attack after zolmitriptan nasal spray. After this her attacks had totally stopped.

At that clinic visit, in order to help her menstruation, which still raged, I started the patient on norethisterone again. Eighteen months later she is still totally free of attacks, and although her bleeding is still very heavy, she is not prepared to even consider allowing me to reininsert an intrauterine device/system, with or without hormones. She says the pain was the worst pain she could ever imagine and as a result she would never, even for the purposes of research, have an IUS inserted again.

This woman appeared to develop a TAC, which approximated most closely to a cluster headache, which she had never had. After having the IUS inserted several attacks were triggered by her face. She did not considered that the IUS had anything to do with her headaches. The attacks would last 20–60 minutes. Both the patient and I were surprised that it was the IUS itself, but the hormone present in the IUS, which triggered the attacks, however this seems unlikely. The patient continued to have large doses of progestogen prior to IUS insertion with no ill effects and has also had large doses following IUS removal. The progestogen dose in the IUS is effective for 6 days and unlikely have reached a high level after only 6 hours. Conversely, if the problem were the hormone in the IUS, its removal would be unlikely to cause the hormone level to decrease significantly in 6 hours.

In summary, on the face of it this would appear to be a simple case of a woman having an IUS inserted and developing a TAC, which was rapidly cured by removing the device. I would be delighted to discover if any of the Journal’s readers have observed a similar case.

Susan L Lipscombe, MBChB, MRCGP
Park Crescent New Surgery, Brighton, UK. E-mail: suelpipscombe@btinternet.com

Informed consent for IUD fitting

Perforation of the uterus is a rare complication of intrauterine device (IUD) fitting. It is quoted as occurring in up to 2 in 1000 insertions. Risk factors for perforation include previous caesarean section2 and postpartum insertion up to 6 months after delivery. This perforation may occur during the sounding of the uterus or the device itself may perforate the uterus. This can lead to the device being free in

References


3 MRCOG, MFSRH
Consultant in General Obstetrics and Gynaecology, Gloucestershire Hospitals NHS Trust, Cheltenham General Hospital, Sandford Road, Cheltenham, UK.

Maud Van de Venne, attesten Maastricht, MRCOG Specialist Registrar, Gloucestershire Hospitals NHS Trust, Cheltenham General Hospital, Sandford Road, Cheltenham, UK.

J Shefras, MRCOG, MFSRH
Consultant in Sexual Health and Reproductive Medicine, Gynaecology, Nuffield Hospital, Cheltenham General Hospital, Cheltenham, UK.

©FSRH J Fam Plann Reprod Health Care 2009: 35(2)